financial post
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
Financial Post • 3 MONTHS AGO
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
Financial Post • 3 MONTHS AGO
Waaree Energies’ IPO Taps Into a 357% Rally in Renewable Stocks in India
Financial Post • 3 MONTHS AGO